Press-release for stocks related to vax-24 for ppruf

| -20.29% | O: -0.59% H: 0.27% C: -1.83%
PPRUY | $36.825 310K

| -20.07% | O: -1.85% H: 0.2% C: -0.07%
PCVX | $62.47 0.13% 300K

| -13.0% | O: 0.2% H: 0.18% C: -0.42%
STRO M | $4.005 -3.26% 310K

| -16.36% | O: 0.2% H: 1.81% C: -3.43%
vax-24 disease pneumococcal study

Vaxcyte Advances to Second Stage of Ongoing Phase 2 Study Evaluating VAX-24 for the Prevention of Invasive Pneumococcal Disease in Infants
Published: 2023-07-11 (Crawled : 12:20) - globenewswire.com
PPRUF | $368.87 610

| -30.13% | O: 3.26% H: 0.0% C: -0.57%
PPRUY | $36.825 310K

| -30.53% | O: 1.02% H: 0.9% C: 0.75%
PCVX | $62.47 0.13% 300K

| 31.04% | O: -2.77% H: 2.2% C: 0.65%
STRO M | $4.005 -3.26% 310K

| -12.84% | O: -1.47% H: 1.71% C: 0.64%
vax-24 disease pneumococcal ongoing study

Vaxcyte Reports Positive Data from Phase 2 Study of its 24-Valent Pneumococcal Conjugate Vaccine Candidate, VAX-24, in Adults Aged 65 and Older and Full Six-Month Safety Data from Adult Phase 1/2 and Phase 2 Studies
Published: 2023-04-17 (Crawled : 11:00) - globenewswire.com
PPRUF | $368.87 610

| -40.84% | O: 0.05% H: 1.69% C: -1.81%
PPRUY | $36.825 310K

| -41.96% | O: -2.08% H: 0.03% C: -0.19%
PCVX | $62.47 0.13% 300K

| 70.93% | O: 15.18% H: 6.42% C: 0.71%
STRO M | $4.005 -3.26% 310K

| -5.91% | O: 0.68% H: 8.13% C: 5.64%
vax-24 pneumococcal vaccine positive study phase 2

Vaxcyte Doses First Participants in Phase 2 Study Evaluating VAX-24 for the Prevention of Invasive Pneumococcal Disease in Infants
Published: 2023-03-30 (Crawled : 15:00) - biospace.com/
PPRUF | $368.87 610

| -41.13% | O: 2.52% H: 2.74% C: 2.74%
PPRUY | $36.825 310K

| -41.94% | O: 1.88% H: 1.04% C: 0.57%
PCVX | $62.47 0.13% 300K

| 69.31% | O: -0.52% H: 0.55% C: -1.06%
STRO M | $4.005 -3.26% 310K

| -13.21% | O: -1.05% H: 2.86% C: -5.08%
vax-24 disease pneumococcal study phase 2

Vaxcyte Announces FDA Clearance of Investigational New Drug Application for VAX-24 for the Prevention of Invasive Pneumococcal Disease in Infants
Published: 2023-02-21 (Crawled : 14:00) - biospace.com/
PPRUF | $368.87 610

| -42.2% | O: -3.64% H: 3.09% C: 1.33%
PPRUY | $36.825 310K

| -41.94% | O: -1.68% H: 1.12% C: -0.58%
PCVX | $62.47 0.13% 300K

| 41.09% | O: -0.93% H: 1.96% C: 0.55%
STRO M | $4.005 -3.26% 310K

| -33.44% | O: -1.13% H: 5.37% C: -0.98%
vax-24 fda clearance drug disease application pneumococcal

Vaxcyte’s VAX-24 Granted FDA Breakthrough Therapy Designation for the Prevention of Invasive Pneumococcal Disease in Adults
Published: 2023-01-05 (Crawled : 15:00) - biospace.com/
PPRUF | $368.87 610

| -30.88% | O: 1.3% H: 2.07% C: 1.45%
PPRUY | $36.825 310K

| -32.07% | O: 0.44% H: 0.55% C: -0.17%
PCVX | $62.47 0.13% 300K

| 33.14% | O: -0.13% H: 0.45% C: -1.58%
STRO M | $4.005 -3.26% 310K

| -48.89% | O: -0.86% H: 7.35% C: 5.23%
vax-24 fda designation disease granted therapy pneumococcal

Vaxcyte Provides Positive Regulatory Updates for VAX-24 Adult and Pediatric Programs
Published: 2022-08-04 (Crawled : 17:00) - biospace.com/
PPRUF | $368.87 610

| -33.2% | O: 0.0% H: 5.96% C: 2.52%
PPRUY | $36.825 310K

| -34.59% | O: 0.04% H: 1.21% C: 0.78%
PCVX | $62.47 0.13% 300K

| 154.76% | O: 1.43% H: 3.54% C: 3.14%
STRO M | $4.005 -3.26% 310K

| -22.91% | O: 1.68% H: 1.28% C: 0.55%
vax-24 positive

Vaxcyte Completes Enrollment of Phase 2 Portion of Phase 1/2 Clinical Proof-of-Concept Study Evaluating Safety, Tolerability and Immunogenicity of VAX-24 in Adults
Published: 2022-07-12 (Crawled : 21:00) - biospace.com/
PPRUF | $368.87 610

| -24.78% | O: 2.74% H: 2.49% C: -1.33%
PPRUY | $36.825 310K

| -25.77% | O: 0.0% H: 2.58% C: 1.33%
PCVX | $62.47 0.13% 300K

| 171.38% | O: -0.43% H: 3.17% C: -0.52%
STRO M | $4.005 -3.26% 310K

| -29.95% | O: 0.0% H: 3.33% C: 2.88%
vax-24 study phase 1 phase 2

Vaxcyte Doses First Participants in Phase 2 Portion of Ongoing VAX-24 Phase 1/2 Clinical Proof-of-Concept Study in Adults
Published: 2022-04-04 (Crawled : 13:00) - biospace.com/
PPRUF | $368.87 610

| -41.46% | O: 3.35% H: 0.0% C: -3.24%
PPRUY | $36.825 310K

| -42.34% | O: 0.03% H: 1.08% C: 0.94%
PCVX | $62.47 0.13% 300K

| 162.03% | O: -0.8% H: 10.94% C: 7.96%
STRO M | $4.005 -3.26% 310K

| -51.64% | O: 0.47% H: 3.37% C: 2.67%
vax-24 ongoing phase 1 phase 2

Vaxcyte Doses First Participants in Phase 1/2 Clinical Study Evaluating VAX-24 for the Prevention of Invasive Pneumococcal Disease and Pneumonia in Adults
Published: 2022-02-23 (Crawled : 22:00) - globenewswire.com
PPRUF | $368.87 610

| -50.15% | O: -8.77% H: 6.66% C: 5.47%
PPRUY | $36.825 310K

| -49.17% | O: -5.49% H: 3.87% C: 3.65%
PCVX | $62.47 0.13% 300K

| 208.25% | O: -8.4% H: 22.28% C: 21.9%
STRO M | $4.005 -3.26% 310K

| -49.82% | O: -1.09% H: 8.21% C: 8.09%
vax-24 disease phase 1 pneumococcal

Vaxcyte Announces FDA Clearance of Investigational New Drug Application for VAX-24 for the Prevention of Invasive Pneumococcal Disease
Published: 2022-01-06 (Crawled : 15:00) - biospace.com/
PPRUF | $368.87 610

| -54.81% | O: 2.64% H: 0.0% C: -0.39%
PPRUY | $36.825 310K

| -55.4% | O: -0.99% H: 0.0% C: -1.16%
PCVX | $62.47 0.13% 300K

| 160.94% | O: 4.14% H: 2.57% C: -1.0%
STRO M | $4.005 -3.26% 310K